The Rise of Chief AI Officers in Big Pharma

This month, Eli Lilly announced the appointment of its first Chief AI Officer (CAIO) - Thomas Fuchs. There is a growing trend in the hiring of CAIOs in Big Pharma. Pfizer appointed their CAIO - Berta Rodriguez-Hervas - back in August. Merck appointed Walid Mehanna as their Chief Data & AI Officer back in 2023. It will not be a surprise if other Pharma companies follow suit to appoint CAIOs.

Multimillion-Dollar Investments in GenAI Biotech Startups

Investments in biotech companies with Generative AI platforms dominated this month’s news:

• Antiverse raised $4.6M to advance its Generative AI Antibody design platform and progress antibodies targeting G-Protein Coupled Receptors and Ion Channels.

• Shift Bioscience raised $16M to advance their cell simulation Generative AI platform and accelerate the identification of safe rejuvenation genes, a fundamental step forward in the development of therapeutics, to treat age-related diseases.

• Terray Therapeutics raised $120M to enhance its small molecule drug discovery/development Generative AI platform (tNova) and also progress internal programs into clinical trials.

1. Syngenta launches Cropwise AI - a GenAI crop management platform designed to increase the efficiency of agronomic advisors and for growers to determine the best crop management practices. Syngenta Group

2. Shape Therapeutics unveils Generative AI model (DeepREAD) for precise and efficient RNA editing. GlobeNewswire

3. IQVIA announces the IQVIA AI Assistant, a generative AI technology with a user-friendly, conversational text interface that provides immediate and intuitive analytics insights. IQVIA

Sign up here and catch up on the The GenAI Biotech Report: Your monthly update of Generative AI applications in Biotech, Pharma, and Life Sciences.